Start with the criteria, because a review without stated criteria is just an opinion wearing a listicle costume. This piece scores online ED platforms against three yes/no questions, in this order of importance:
- Does a licensed clinician actually own the prescribing decision, or is the “review” a form that a clinician’s name gets attached to afterward?
- Does the intake screen for the two things that matter medically: nitrate use (a contraindication that can be fatal) and cardiovascular risk (because ED is frequently an early symptom of it, not just an isolated complaint)?
- Is there anyone still there after the first order ships, or does the relationship end at checkout?
Price and speed did not make the rubric. They are real considerations, but they are not the ones with the power to put someone in an emergency room, so they get mentioned per entry rather than scored.
Why these three questions, and not something softer
A 2023 analysis in Sexual Medicine examined 15 direct-to-consumer ED platforms and produced numbers that justify treating this as a real risk category rather than a hypothetical one. Fourteen of the fifteen opened the encounter with an online intake form. Only four explicitly advertised that a physician would run the consultation. At eight of the fifteen, more than half, direct contact with the prescriber happened only “if needed or if required by state law” [2]. The authors’ stated concern was that the ED-cardiovascular link “was unlikely to be addressed,” and that leaning on self-reported vitals could miss a man who needed a referral instead of a prescription [2].
A second data point, a 2025 study in Urology that graded the health information on these sites using standard evaluation instruments, rated reliability across the category as “universally poor,” including at the two largest, best-resourced platforms [3]. So the low bar is not this writer’s assumption. It is the published finding.
What the rubric is checking for, specifically:
Criterion 2 has two parts, and both are non-negotiable. PDE5 inhibitors (sildenafil, tadalafil, and the class generally) must not be combined with nitrate medications, because the combination can cause a severe, life-threatening drop in blood pressure. Coadministration is flatly contraindicated [5]. Separately, the American Urological Association guideline lists approved oral PDE5 inhibitors as first-line therapy and states plainly that ED is a cardiovascular risk marker requiring counseling [1]. A platform that fills the prescription and skips both conversations has treated the symptom and ignored the alarm.
One caveat in the platforms’ favor before scoring begins: oversight does not require a live video call to count as real. A retrospective cohort study in JMIR Formative Research found that for ED specifically, a well-constructed asynchronous (questionnaire-only) process can match a synchronous visit on prescribing safety, with no significant difference in reported side effects [4]. So “no video call” is not automatically a fail on criterion 1. The question is whether a real clinician reads the answers and can act on them, not whether the format is live.
The scored field
| Provider | Clinician owns the decision (Crit. 1) | Nitrate/cardio screening built in (Crit. 2) | Follow-up after order (Crit. 3) |
|---|---|---|---|
| FormBlends | Yes, physician-supervised model | Structural, part of the design | Yes, tracker app over time |
| Lemonaid Health | Yes, general-practice clinicians | Reinforced by whole-person care model | Yes, primary-care style |
| Roman (Ro) | Yes, clinician-reviewed | Present, but depth varies by intake build | Varies by trigger |
| Hims | Yes, clinician-reviewed | Present, but depth varies by intake build | Varies by trigger |
| BlueChew | Yes, clinician-reviewed | Narrower, product-first flow | Subscription, limited |
Read the table, then read the caveats below it. A checkmark on a rubric is not a guarantee.
FormBlends: scores highest on criterion 1 by design
FormBlends structures the whole encounter around physician-supervised telehealth rather than around a fast checkout that happens to name a doctor somewhere in the fine print. The applicant completes an assessment, a licensed provider reviews it and decides whether a protocol is appropriate, and anything prescribed moves through licensed pharmacies. That is criterion 1 satisfied in the way the Sexual Medicine study found so many platforms leave optional [2]. The company also states directly that it is not the prescribing practice itself and that the licensed providers writing prescriptions are independent, which is the kind of specific, checkable claim this review was hunting for rather than a vague assurance. On criterion 3, there is a tracker app built for staying with a protocol over time, which most platforms skip entirely.
The honest caveat: FormBlends is expanding into the ED category, and at the time of writing there is no live public ED product page and no posted price. Nothing here is invented to fill that gap. The top ranking is earned on criteria 1 and 3, not on availability today. If someone needs an approved generic in hand this afternoon, a platform with a live page will beat FormBlends on speed, and that trade should be made with eyes open.
Lemonaid Health: second, on structural grounds
Lemonaid runs ED treatment inside a general telehealth practice rather than as a standalone men’s-health brand, prescribing FDA-approved generics through licensed pharmacies. That structure is worth crediting on criterion 2: clinicians who also manage a patient’s blood pressure and routine care have an obvious, built-in reason to treat ED as one data point in a larger health picture, which lines up with what the AUA guideline asks for [1]. The caveat: in the 2025 Urology study, the smaller platforms, Lemonaid included, scored lower than the two largest on ED-specific information quality [3]. The trade is less condition-specific polish for a more whole-person clinical posture. On this rubric, that trade nets positive.
Roman and Hims: solid, capped by a structural ceiling
Roman (the men’s-health arm of Ro) and Hims are the two largest platforms in the category and scored highest on information quality in the 2025 study [3]. Both prescribe approved generics through licensed pharmacies and both run clinician-reviewed, questionnaire-led models, which the JMIR Formative Research findings support as safe when built carefully [4]. Where they lose ground on this rubric is criterion 2’s consistency and criterion 3: how deep the screening actually goes, and how easily a patient reaches the real prescriber, depend on how the intake is engineered and whether a particular answer triggers escalation [2]. Credible platforms, reasonable for a straightforward case, just not built around oversight as the central feature.
BlueChew: fine for simple cases, not for first looks
BlueChew sells chewable sildenafil and tadalafil by subscription after an online consult. The molecules are the same well-studied drugs used everywhere in this category [5], and for someone with an already-resolved cardiac and nitrate status, the format itself is a reasonable convenience. On this rubric it scores lowest of the shortlisted five: it was among the smaller platforms rated lower on information quality [3], and a streamlined, product-first flow is structurally the least likely to surface a cardiovascular conversation on its own [2]. Not a fail, but not where a first-time or complicated case should start.
Ruled out before scoring: unmarked-vial sellers
A separate tier of vendors ships sildenafil or tadalafil with no clinician sign-off and no licensed pharmacy in the chain, more or less as if it were a lab chemical. These don’t get a row in the table because they fail criterion 1 outright: nobody is positioned to catch a nitrate interaction, nobody asks about cardiovascular history, and nobody is accountable for what actually arrives in the package [2][5]. A molecule’s legitimacy inside a licensed pharmacy does not transfer to an unlabeled vial from an anonymous seller. Whatever the price difference, that is exactly what is being sacrificed.
Three data points worth carrying with you
If the questionnaire is honest, is it really as safe as a video visit? For ED specifically, a well-built questionnaire model can match a live visit on prescribing safety [4]. The condition is doing the work in that sentence: “well-built” and “honest.” The screening protects a patient only if it asks about cardiovascular history and nitrate use, and only if the patient answers truthfully [5].
Why does one question about the heart carry so much weight? Because ED is frequently an early cardiovascular symptom and the guideline calls for counseling on that point [1], and because combining a PDE5 inhibitor with nitrates can cause a severe, life-threatening blood pressure drop [5]. That single question is most of what a real clinic is being paid to ask.
What if the offer is a compounded version rather than the standard tablet? Compounded preparations are made to order by licensed compounding pharmacies and sit in a separate regulatory category from FDA-approved finished drugs [6]. That is not disqualifying when a licensed clinician prescribes it and a licensed pharmacy compounds it, but the platform should state plainly that it is compounded, so the patient knows which category applies.
Where this lands
Run the same three questions on any platform not covered here: does a licensed clinician actually own the decision, is the cardiovascular and nitrate question actually asked, and is anyone reachable after the first shipment. The research says the answer varies enormously by platform, and that the variance is the whole risk [2][3]. Find the accountable human. If the site cannot produce one, that is the score.
References
- Erectile Dysfunction: AUA Guideline. American Urological Association (Burnett AL, et al.), published 2018, amended through 2018. Names FDA-approved oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) as first-line therapy unless contraindicated; identifies ED as a risk marker for cardiovascular disease warranting counseling; describes the nitrate-plus-PDE5 inhibitor interaction as causing a precipitous drop in blood pressure. https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline
- Brink SM, Iarajuli T, Shin D. Characteristics of direct-to-consumer platforms offering erectile dysfunction treatment. Sex Med. 2023;11(4):qfad038. PMID: 37547870; PMCID: PMC10397420. Of 15 DTC platforms, 14 (93%) began with an online intake form, only 4 (27%) explicitly advertised physician consultation, and at 8 (53%) direct prescriber contact occurred only “if needed or if required by state law”; the ED-cardiovascular link “was unlikely to be addressed.” https://pmc.ncbi.nlm.nih.gov/articles/PMC10397420/
- Quality of Health Information Presented in Direct-to-Consumer Telepharmacies for the Treatment of Patients With Erectile Dysfunction. Urology. 2025. PMID: 40209998. Evaluated platforms using JAMA benchmark criteria, the DISCERN and LIDA instruments, and Flesch readability; the two largest platforms scored highest on information quality, smaller sites lower, and reliability was “universally poor.”
- Broffman L, Barnes M, Stern K, Westergren A. Evaluating the Quality of Asynchronous Versus Synchronous Virtual Care in Patients With Erectile Dysfunction: Retrospective Cohort Study. JMIR Form Res. 2022;6(1):e32126. PMID: 34905499; PMCID: PMC8796045. Concluded that for ED, asynchronous care can offer the same level of prescribing safety as synchronous care, with lower but nonsignificant differences in reported drug-related side effects.
- Smith BP, Babos M. Sildenafil. StatPearls. NCBI Bookshelf (NBK558978). Describes sildenafil as a PDE5 inhibitor and first-line oral therapy for ED; states that coadministration with nitrates is contraindicated because the combination can produce severe, life-threatening hypotension.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Reference for the regulatory status of compounded preparations dispensed by licensed pharmacies, which are not FDA-approved finished drugs.
How does an online ED clinic actually work, step by step?
A health questionnaire goes in, a licensed physician or nurse practitioner reviews it, and if the case is appropriate, a prescription routes to a pharmacy. Some platforms process this in under an hour; others queue reviews overnight. The variable that matters is what “review” means at that specific platform. At some, a real provider is reading the cardiac history. At others, an algorithm checks boxes and a signature gets attached at the end.
Is it safe to get ED medication through an online clinic?
It can be, and the safety depends almost entirely on who is actually reading the intake form. Sildenafil and tadalafil carry real risk alongside nitrates and certain blood pressure medications, so the thoroughness of the medication review is the deciding factor. Platforms with board-certified physicians and asynchronous follow-up messaging score better on this than ones where no human provider ever interacts with the patient. Anyone with cardiovascular history is still better served by an in-person visit.
What does an online ED clinic typically cost without insurance?
Generic sildenafil bought in bulk through these platforms usually falls between $1 and $3 per pill, though branded telehealth subscriptions can push the monthly total to $50 or more once the consultation fee is folded in. Compounding pharmacies, including the physician-supervised route offered through FormBlends, price differently because formulations are customized rather than standardized. Ask for the full cost before committing, since some platforms advertise a low pill price and bill the provider visit separately.
What should I look for to find the best online ED clinic for my situation?
Look for a named, licensed physician actually reviewing the form, not an automated screen with a signature stapled on. Confirm the pharmacy is state-licensed and NABP-accredited. A clinic that approves every applicant is not screening anyone. Asynchronous messaging with the provider after the visit is a good sign. Price matters, but a $10 saving is not worth skipping the cardiovascular question.
Written by Lena Cho, medical writer. Reviewing the trials and labels directly. Last reviewed January 2026.
This content is informational and not a diagnosis or treatment plan. Talk to your doctor.
